Rituximab in steroid resistant nephrotic syndrome

  • Agomoni Chaki Resident ,Phase B,Department of Pediatric Nephrology,Bangabondhu Sheikh Mujib Medical University
  • Farhana Rahman Resident ,Phase B,Department of Pediatric Nephrology,Bangabondhu Sheikh Mujib Medical University
  • Jahanara Arju Resident ,Phase B,Department of Pediatric Nephrology,Bangabondhu Sheikh Mujib Medical University
  • Abdullah- Al Mamun Assistant professor,Bangabondhu Sheikh Mujib Medical University
  • Tahmina Jesmin Associate professor,Bangabondhu Sheikh Mujib Medical University
  • Sayed Saimul Huque Associate professor,Bangabondhu Sheikh Mujib Medical University
  • Afroza Begum Associate professor,Bangabondhu Sheikh Mujib Medical University
  • Habibur Rahman Professor, Dept of Pediatric Nephrology,Bangabondhu Sheikh Mujib Medical University
  • Goam Muin Uddin Professor, Dept of Pediatric Nephrology,Bangabondhu Sheikh Mujib Medical University
  • Ranjit Ranjan Roy Professor & chairman, Dept of Pediatric Nephrology,Bangabondhu Sheikh Mujib Medical University
DOI: https://doi.org/10.14238/pi59.4.2019.175-82
Keywords: nephrotic syndrome; Rituximab; steroid resistant

Abstract

Background Nephrotic syndrome (NS) is one of the most common glomerular disease in children, characterized by massive proteinuria, hypoalbuminemia, dyslipidemia and edema. Steroid-resistant nephrotic syndrome (SRNS) and steroid-dependent nephrotic syndrome (SDNS) present challenges in pharmaceutical management. Patient need several immunosuppressant for optimal control, each of which has significant side effect and difficult to get  desired results. Rituximab (RTX) is a monoclonal antibody that targets B cells and has been shown to be effective for patients with SRNS and SDNS.

Objective To see efficacy of RTX in pediatric patients with SRNS.

Method This retrospective study took place in Pediatric Nephrology Department of Bangabandhu Sheikh Mujib Medical University from July 2017 to June 2019. Patients diagnosed with SRNS who were treated with RTX and followed up for 6 months were enrolled in this study. Primary endpoint was achievement of remission after rituximab infusion; secondary endpoint was relapse-free survival rate in 6 months period following rituximab infusion.

Results Total  7 patients were recruited in this study. Among them 4 were male. Clinical and lab parameters of all patients before and after RTX  were compared. Complete remission achieved in 4/7 patients, partial remission in 2/7 patients and no response in 1/7 patient. Mean number of relapse in 3 patients before RTX infusion was 3.67 (SD 0.57) and after 0.33 (SD 0.00) (P=0.038).

Conclusion RTX is a biological agent that is effective and promising drug in children with SRNS. Rituximab is useful to induce and maintain remission.

References

1. McEnery PT, Strife CF. Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesengial proliferation, or focal glomerulosclerosis. Pediatr Clin North Am. 1982; 29: 875-94.
2. Sharples PM, Poulton J, White RH. Steroid responsive nephritic syndrome is more common in Asian. Arch Dis Child. 1985; 60: 1014 - 17
3. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens. 2001; 10: 543-9.
4. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephritic syndrome. Nat Genet. 2000; 24: 349-54.
5. Caridi G, Bertelli R, Di Duca M, Dagnino M, Emma F, Onetti Muda A et al. Broadening the spectrum of disease related to podocin mutation. J Am Soc Nephrol. 2003; 14: 1278 - 86
6. Cohen AH, Border WA, Glassock RJ. Nephrotic syndrome with glomerular mesangial IgM deposits. Lab Invest. 1978; 38: 610-19
7. Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol. 1998; 9: 1333-40.
8. McAdams AJ, Valentini RP, Welch TR. The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change. Medicine (Baltimore). 1997; 76: 42-52.
9. Kyrieleis HA, Lowik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, et al. Long-term outcome of biopsy proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009; 4; 1593-600.
10. Ehrich JHH, Geerlings C , Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007; 22: 2183-93.
11. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatic arthritis. 2004; 350: 2572-81.
12. Smith KG, Jones RB, Burns SM, Jayne DR. Long term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006; 54: 2970-82.
13. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology(Oxford). 2006; 45; 1432-36
14. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117- 125
15. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine- dependant nephritic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23: 1269-79.
16. Bagga A, Sinha A, Moudgil A. Rituximab in patients with steroid-resistant nephritic syndrome. N Engl J Med. 2007; 356: 2751-2.
17. Gilbert RD, Hulse E, Rigden S. Riuximab therapy for steroid-dependant minimal change nephrotic syndrome. Pediatr Nephrol. 2006; 21: 1698-700.
18. Kidney disease: improving global outcomes. KDIGO clinical practice guideline for glomerulonephritis. June 2012; http://kdigo.org/home/glomerulonephritis-gn/
19. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteriafor Adverse Events (CTCAE) Version 4.0. Bethesda. NIH Publication; 2009. p. 2-79.
20. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011; 3: 85ra46.
21. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol. 2006; 177: 4481- 87
22. Bertelli R, Trivelli A, Magnasco A, Cioni M, Bodria M, Carrea A et al. Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome. Clin Exp Immunol. 2010; 161: 151-58
23. Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol. 2009; 24: 1433-38
24. Prytu?a A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010; 25: 461-68
25. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and dependant nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010; 5: 2207 -212
26. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012; 23: 1117-24.
27. Alaifan A, Jamjoom AA, Aldeen RJ, Harari MF. Rituximab efficacy in padiatric patients with refractory nephrotic syndrome. Int J Res Med Sci. 2017; 5: 1312-15
28. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012; 27: 1910-15
29. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo- controlled trial. Lancet. 2014; 384: 1273-81.
30. Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013; 84: 1025-33.
31. Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, et al. Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Nephrol. 2013; 38: 483-88.
32. Safdar OY, Aboualhaleem A, Kari JA. Rituxiab for troublesome cases of childhood nephrotic syndrome. World J Clin Pediatr. 2014; 3: 69-75.
Published
2019-07-16
How to Cite
1.
Chaki A, Rahman F, Arju J, Al Mamun A-, Jesmin T, Huque S, Begum A, Rahman H, Uddin G, Roy R. Rituximab in steroid resistant nephrotic syndrome. PI [Internet]. 16Jul.2019 [cited 17Apr.2024];59(4):175-2. Available from: https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2168
Issue
Vol 59 No 4 (2019): July 2019
Section
Pediatric Nephrology

Copyright (c) 2019 Agomoni Chaki, Farhana Rahman, Jahanara Arju, Abdullah- Al Mamun, Tahmina Jesmin, Sayed Saimul Huque, Afroza Begum, Habibur Rahman, Goam Muin Uddin, Ranjit Ranjan Roy

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Received 2019-03-24
Accepted 2019-07-16
Published 2019-07-16